[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-detail-123738-en":3,"doc-seo-123738-105":30,"detail-sidebar-cat-0-en-105":91},{"code":4,"msg":5,"data":6},0,"success",{"doc_id":7,"user_id":8,"nickname":9,"user_avatar":10,"doc_module":4,"category_id":11,"category_name":12,"doc_title":13,"doc_description":14,"doc_content":15,"file_id":16,"file_url":17,"file_type":18,"file_size":19,"view_count":4,"is_deleted":4,"is_public":20,"is_downloadable":20,"audit_status":20,"page_count":21,"language":22,"language_code":23,"site_id":24,"html_lang":23,"table_of_contents":25,"faqs":26,"seo_title":27,"seo_description":14,"update_tm":28,"read_time":29},123738,16904993612988,"Olivia Brown","https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd",8,"Research & Report","Using Machine Learning to Individualize Treatment Effect Estimation - Challenges and Opportunities","The use of data from randomized clinical trials to justify treatment decisions for real world patients represents current best practice, but it depends on extrapolating average treatment effects to individuals whose characteristics differ from trial participants. Because treatment effects vary across patients and between trial and real-world populations, this assumption can fail for many patients. Machine learning for estimating Conditional Average Treatment Effects (CATE) from observational data enables more accurate, patient-specific effect predictions. This review covers key challenges and opportunities, including identification assumptions, covariate shift, learning without true labels, and applications, future work, and collaborations to improve CATE utility and patient benefit.","1 Using Machine Learning to Individualize Treatment Effect  \n2 Estimation: Challenges and Opportunities 3  \n4 Alicia Curth 1 , Richard W Peck2,3 , Eoin McKinney4,5 , James Weatherall6 , 5 Mihaela van der Schaar 1,5,7  \n6 1 Department of Applied Mathematics & Theoretical Physics, University of Cambridge, 7 Cambridge, UK  \n8 2 Department of Pharmacology & Therapeutics, University of Liverpool, Liverpool, UK  \n9 3 Roche Pharma Research & Early Development (pRED), Roche Innovation Center, Basel, 10 Switzerland  \n11 4 Cambridge Institute for Immunotherapy & Infectious Disease, Jeffrey Cheah Biomedical  \n12 Center, Cambridge Biomedical Campus, Addenbrooke’s Hospital, Cambridge, UK.  \n13 5 Cambridge Centre for AI in Medicine, Cambridge, UK.  \n14 6 AstraZeneca R&D Data Science and Artificial Intelligence, Cambridge, UK.  \n15 7 The Alan Turing Institute, London, UK.  \n16  \n17 Corresponding author: Alicia Curth, [amc253@cam.ac.uk](amc253@cam.ac.uk)  \n18 Key words: Conditional Average Treatment Effect, Treatment individualization, Precision  \n19 medicine, Machine learning  \n20 ORCID IDs  \n21 AC: 0009-0009-4452-378X  \n22 RWP: 0000-0003-1018-9655  \n23 EM: 0000-0003-3516-3072  \n24 JW: 0009-0004-5601-4708  \n25 MvdS: 0000-0003-3933-6049  \n26 CONFLICT OF INTEREST  \n27 RWP receives compensation from and holds stock in F Hoffmann la Roche. JW receives  \n28 compensation from and holds stock in AstraZeneca. The Cambridge Center for AI in  \n29 Medicine which MvdS is leading is funded by AstraZeneca and GSK. All other authors  \n30 declare no conflicts of interest.  \n31 FUNDING  \n32 AC is a PhD student funded by AstraZeneca.  \n33  \n34 ABSTRACT  \n35 The use of data from randomized clinical trials to justify treatment decisions for real world  \n36 patients is the current state ofthe art. It relies on the assumption that average treatment  \n37 effects from the trial can be extrapolated to patients with personal and/or disease  \n38 characteristics different from those treated in the trial. Yet, because of heterogeneity of  \n39 treatment effects between patients and between the trial population and real-world patients, 40 this assumption may not be correct for many patients. Using machine learning to estimate the  \n41 expected Conditional Average Treatment Effect (CATE) in individual patients from  \n42 observational data offers the potential for more accurate estimation of the expected treatment  \n43 effects in each patient based on their observed characteristics. In this review we discuss some  \n44 of the challenges and opportunities for machine learning to estimate CATE, including  \n45 ensuring data identification assumptions are met, managing covariate shift and learning  \n46 without access to the true label of interest. We also discuss the potential applications as well  \n47 as future work and collaborations needed to further improve identification and utilization of  \n48 CATE estimates to increase patient benefit.  \n49 INTRODUCTION  \n50 Healthcare professionals try to make treatment decisions about individual patients using the  \n51 best available evidence. In such evidence-based medicine, the data informing these individual  \n52 patient decisions often comes from randomized clinical trials in populations of patients who  \n53 have the same disease as the patient needing treatment now. The underlying assumption is  \n54 that the patient needing treatment is similar to those studied in the clinical trials and will  \n55 respond in a similar manner. Yet this assumption is often not correct and there would be great  \n56 benefit in having better methods to estimate expected effect in each individual patient. Such  \n57 methods could be developed either during trials of novel medicines or from real-world  \n58 evidence generated after approval, and – assuming they provide a net benefit – accompany  \n59 those medicines as they are approved and embedded in healthcare systems around the world. 60  \n61 The problems with clinical trial evidence  \n62 Randomized cont","cbCairbaNmVezWvh","https://ap.wps.com/l/cbCairbaNmVezWvh","pdf",344184,1,37,"English","en",105,"# Abstract\n# Introduction\n## The problems with clinical trial evidence\n## Limitations of average treatment effects\n## Heterogeneity of treatment effects and subgroup variation\n## Machine learning for individual-level effect estimation\n## Challenges: identification, covariate shift, and missing labels\n## Applications and future directions","[{\"question\":\"Why can randomized clinical trial evidence fail for real-world patients?\",\"answer\":\"It relies on extrapolating average treatment effects from trial participants to patients with different personal and/or disease characteristics. Treatment effect heterogeneity between patients and between trial and real-world populations can make this extrapolation incorrect for many individuals.\"},{\"question\":\"What does Conditional Average Treatment Effect (CATE) estimation aim to do?\",\"answer\":\"It estimates the expected CATE for individual patients from observational data using machine learning. This supports more patient-specific estimation of expected treatment effects based on observed characteristics.\"},{\"question\":\"Which challenges are discussed for machine learning CATE estimation?\",\"answer\":\"Key challenges include ensuring data identification assumptions are met, managing covariate shift, and learning without access to the true label of interest.\"}]","Using Machine Learning to Individualize Treatment Effect Estimation - Challenges and Opportunities | PDF",1785818261,93,{"code":4,"msg":31,"data":32},"ok",{"site_id":24,"language":23,"slug":33,"title":13,"keywords":34,"description":14,"schema_data":35,"social_meta":86,"head_meta":88,"extra_data":90,"updated_unix":28},"using-machine-learning-to-individualize-treatment-effect-estimation-challenges-and-opportunities","",{"@graph":36,"@context":85},[37,54,68],{"@type":38,"itemListElement":39},"BreadcrumbList",[40,44,48,51],{"item":41,"name":42,"@type":43,"position":20},"https://docshare.wps.com","Home","ListItem",{"item":45,"name":46,"@type":43,"position":47},"https://docshare.wps.com/document/","Document",2,{"item":49,"name":12,"@type":43,"position":50},"https://docshare.wps.com/document/research-report/",3,{"item":52,"name":13,"@type":43,"position":53},"https://docshare.wps.com/document/using-machine-learning-to-individualize-treatment-effect-estimation-challenges-and-opportunities/123738/",4,{"url":52,"name":13,"@type":55,"author":56,"headline":13,"publisher":58,"fileFormat":61,"inLanguage":23,"description":14,"dateModified":62,"datePublished":62,"encodingFormat":61,"isAccessibleForFree":63,"interactionStatistic":64},"DigitalDocument",{"name":9,"@type":57},"Person",{"url":41,"name":59,"@type":60},"DocShare","Organization","application/pdf","2026-08-04",true,{"@type":65,"interactionType":66,"userInteractionCount":4},"InteractionCounter",{"@type":67},"ViewAction",{"@type":69,"mainEntity":70},"FAQPage",[71,77,81],{"name":72,"@type":73,"acceptedAnswer":74},"Why can randomized clinical trial evidence fail for real-world patients?","Question",{"text":75,"@type":76},"It relies on extrapolating average treatment effects from trial participants to patients with different personal and/or disease characteristics. Treatment effect heterogeneity between patients and between trial and real-world populations can make this extrapolation incorrect for many individuals.","Answer",{"name":78,"@type":73,"acceptedAnswer":79},"What does Conditional Average Treatment Effect (CATE) estimation aim to do?",{"text":80,"@type":76},"It estimates the expected CATE for individual patients from observational data using machine learning. This supports more patient-specific estimation of expected treatment effects based on observed characteristics.",{"name":82,"@type":73,"acceptedAnswer":83},"Which challenges are discussed for machine learning CATE estimation?",{"text":84,"@type":76},"Key challenges include ensuring data identification assumptions are met, managing covariate shift, and learning without access to the true label of interest.","https://schema.org",{"og:url":52,"og:type":87,"og:title":13,"og:site_name":59,"og:description":14},"article",{"robots":89,"canonical":52},"index,follow",{"doc_id":7,"site_id":24},{"code":4,"msg":5,"data":92},[93,97,101,105,110,115,120,123,128,131,135],{"id":20,"doc_module":4,"doc_module_name":46,"category_name":94,"show_sort_weight":95,"slug":96},"Story & Novel",90,"story-novel",{"id":47,"doc_module":4,"doc_module_name":46,"category_name":98,"show_sort_weight":99,"slug":100},"Literature",80,"literature",{"id":53,"doc_module":4,"doc_module_name":46,"category_name":102,"show_sort_weight":103,"slug":104},"Exam",70,"exam",{"id":106,"doc_module":4,"doc_module_name":46,"category_name":107,"show_sort_weight":108,"slug":109},5,"Comic",60,"comic",{"id":111,"doc_module":4,"doc_module_name":46,"category_name":112,"show_sort_weight":113,"slug":114},6,"Technology",50,"technology",{"id":116,"doc_module":4,"doc_module_name":46,"category_name":117,"show_sort_weight":118,"slug":119},7,"Healthcare",40,"healthcare",{"id":11,"doc_module":4,"doc_module_name":46,"category_name":12,"show_sort_weight":121,"slug":122},30,"research-report",{"id":124,"doc_module":4,"doc_module_name":46,"category_name":125,"show_sort_weight":126,"slug":127},9,"Religion & Spirituality",20,"religion-spirituality",{"id":126,"doc_module":4,"doc_module_name":46,"category_name":129,"show_sort_weight":126,"slug":130},"World Cup","world-cup",{"id":132,"doc_module":4,"doc_module_name":46,"category_name":133,"show_sort_weight":132,"slug":134},10,"Lifestyle","lifestyle",{"id":136,"doc_module":4,"doc_module_name":46,"category_name":137,"show_sort_weight":106,"slug":138},19,"General","general"]